The following is a summary of the VolitionRx Limited (VNRX) Q4 2023 Earnings Call Transcript:

Financial Performance:

• VolitionRx recorded revenue of $775,000 for the full year 2023, a significantly higher rate compared to the previous year.

• The Q4 revenue showed significantly higher results of $244,000, which is a 104% increase year-on-year.

• Net cash generated from operating activities reached approximately $6.4 million during Q4 and there was a net loss of $8.8 million for the same period.

• By end of the year, the company had $20.7 million in cash and cash equivalents.

• In the full year 2023, net cash used for operating activities was $18.1 million, and the net loss came to $35.7 million.

Business Progress:

• The company's Nu.Q Vet cancer test and Nu.Q discover pipeline observed a considerable increase in revenue, earning $475,000 and $300,000 respectively.

• VolitionRx has strategic partnerships to increase market presence, partnering with IDEXX, Heska Corporation and Fujifilm Vet Systems across multiple regions.

• VolitionRx has ambitious plans for 2024, projecting doubling of Nu.Q Discover revenue and expecting Nu.Q Vet's strong growth to continue with its global and regional partners.

• Looking forward, the company aims to achieve financial stability through non-dilutive funding, milestone payments, licensing deals, and product revenues.

• In their path for expansion, VolitionRx introduced a new method for detecting circulating tumor DNA (ctDNA), called Capture-PCR and is in discussions to license this technology.

More details: VolitionRX IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.